ARQT
ARCUTIS BIOTHERAPEUTICS INC
About ARQT
Arcutis Biotherapeutics, Inc. is a late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for dermatological diseases with unmet medical needs. It harnesses its dermatology development platform to build therapies against biologically validated targets. Its dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions. The company’s lead program, topical roflumilast, has the potential to advance the care for plaque psoriasis of the body and scalp, atopic dermatitis and seborrheic dermatitis. It is developing roflumilast cream for the treatment of plaque psoriasis, including psoriasis in intertriginous regions, such as the groin, axillae and inframammary areas, as well as atopic dermatitis. It is also developing ARQ-252 is topical cream formulation of a potent and selective small molecule inhibitor of JAK1 and is developing it for chronic hand eczema and vitiligo.
Buy US stocks in Australia starting with ARQT. Open an account and start investing today!
$1.01B
-
0.00%
679.73K
$16.89
$16.37
$16.59
$27.40
$12.81
ARQT FAQs
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in ARQT
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.